356 related articles for article (PubMed ID: 32810256)
1. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
2. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
3. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
[TBL] [Abstract][Full Text] [Related]
4. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
6. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
Tang CH; Yu F; Huang CY; Chen DY
Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
[TBL] [Abstract][Full Text] [Related]
9. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.
Mercer LK; Regierer AC; Mariette X; Dixon WG; Baecklund E; Hellgren K; Dreyer L; Hetland ML; Cordtz R; Hyrich K; Strangfeld A; Zink A; Canhao H; Hernandez MV; Tubach F; Gottenberg JE; Morel J; Zavada J; Iannone F; Askling J; Listing J
Ann Rheum Dis; 2017 Dec; 76(12):2025-2030. PubMed ID: 28822981
[TBL] [Abstract][Full Text] [Related]
11. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
[TBL] [Abstract][Full Text] [Related]
12. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
13. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
Barbulescu A; Delcoigne B; Askling J; Frisell T
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
[TBL] [Abstract][Full Text] [Related]
15. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
[TBL] [Abstract][Full Text] [Related]
16. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
17. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
Seror R; Lafourcade A; De Rycke Y; Pinto S; Castaneda J; Fautrel B; Mariette X; Tubach F
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35738803
[TBL] [Abstract][Full Text] [Related]
18. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
[TBL] [Abstract][Full Text] [Related]
19. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
[TBL] [Abstract][Full Text] [Related]
20. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.
Dreyer L; Cordtz RL; Hansen IMJ; Kristensen LE; Hetland ML; Mellemkjaer L
Ann Rheum Dis; 2018 Apr; 77(4):510-514. PubMed ID: 29217620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
